Korean Circ J.  2015 Sep;45(5):386-390. 10.4070/kcj.2015.45.5.386.

Apelin Levels In Isolated Coronary Artery Ectasia

• Bilik MZ
• Kaplan I
• Yildiz A
• Akil MA
• Acet H
• Yuksel M
• Polat N
• Aydin M
• Oylumlu M
• ErtaS F
• Kaya H
• Alan S

• KMID: 2223802
• DOI: http://doi.org/10.4070/kcj.2015.45.5.386

Abstract

BACKGROUND AND OBJECTIVES
The etiopathogenesis of coronary artery ectasia (CAE) is not known completely. In most of the cases, CAE is associated with atherosclerosis; however, isolated CAE has a nonatherosclerotic mechanism. The association between atherosclerotic coronary artery disease and apelin has been examined in previous studies. However, the role of plasma apelin in isolated coronary artery ectasia has not been studied. In this study, we investigated the relationship between plasma apelin levels and isolated coronary artery ectasia.
SUBJECTS AND METHODS
The study population included a total of 54 patients. Twenty-six patients had isolated CAE (53.6+/-8.1 years); 28 patients with normal coronary arteries (51.6+/-8.8 years) and with similar risk factors and demographic characteristics served as the control group. Apelin levels were measured using an enzyme-linked immunoassay kit.
RESULTS
Apelin level in the CAE group was significantly lower (apelin=0.181+/-0.159 ng/mL) than that in the control group (apelin=0.646+/-0.578 ng/mL) (p=0.033). Glucose, creatinine, total cholesterol, triglyceride, low density lipoprotein cholesterol, and high density lipoprotein cholesterol levels were not significantly different between the two groups.
CONCLUSION
In this study, we showed that patients with isolated CAE have decreased plasma apelin levels compared with the control group. Based on the data, a relationship between plasma apelin and isolated CAE was determined.

Keyword

Apelin protein, human; Coronary artery disease; Dilatation, pathologic; Inflammation

MeSH Terms

Atherosclerosis
Cholesterol
Cholesterol, HDL
Cholesterol, LDL
Coronary Artery Disease
Coronary Vessels*
Creatinine
Dilatation, Pathologic*
Glucose
Humans
Immunoassay
Inflammation
Plasma
Risk Factors
Triglycerides
Cholesterol
Cholesterol, HDL
Cholesterol, LDL
Creatinine
Glucose

Figure

• 

  Fig. 1 Comparison of apelin levels between the CAE and control groups. In the CAE group, the mean apelin level is significantly lower (p=0.033). CAE: coronary artery ectasia.

• 

  Fig. 2 The pathophysiological role of apelin in coronary artery ectasia. Apelin is associated with reduced interleukin-6 (IL-6) and Tumor necrosis factor-α (TNF-α) levels. It has been suggested that apelin inhibits macrophage proinflammatory cytokines.

Reference

1. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther. 2005; 107:198–211.

2. Ronkainen VP, Ronkainen JJ, Hänninen SL, et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J. 2007; 21:1821–1830.

3. Chandrasekaran B, Dar O, McDonagh T. The role of apelin in cardiovascular function and heart failure. Eur J Heart Fail. 2008; 10:725–732.

4. Hashimoto T, Kihara M, Ishida J, et al. Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2006; 26:1267–1272.

5. Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001; 99:87–92.

6. Farkasfalvi K, Stagg MA, Coppen SR, et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun. 2007; 357:889–895.

7. Leeper NJ, Tedesco MM, Kojima Y, et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol. 2009; 296:H1329–H1335.

8. Hartnell GG, Parnell BM, Pridie RB. Coronary artery ectasia. Its prevalence and clinical significance in 4993 patients. Br Heart J. 1985; 54:392–395.

9. Yamanaka O, Hobbs RE. Coronary artery anomalies in 126,595 patients undergoing coronary arteriography. Cathet Cardiovasc Diagn. 1990; 21:28–40.

10. Valente S, Lazzeri C, Giglioli C, et al. Clinical expression of coronary artery ectasia. J Cardiovasc Med (Hagerstown). 2007; 8:815–820.

11. Rath S, Har-Zahav Y, Battler A, et al. Fate of nonobstructive aneurysmatic coronary artery disease: angiographic and clinical follow-up report. Am Heart J. 1985; 109:785–791.

12. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol. 2002; 40:43–48.

13. Finkelstein A, Michowitz Y, Abashidze A, Miller H, Keren G, George J. Temporal association between circulating proteolytic, inflammatory and neurohormonal markers in patients with coronary ectasia. Atherosclerosis. 2005; 179:353–359.

14. Turhan H, Erbay AR, Yasar AS, Balci M, Bicer A, Yetkin E. Comparison of C-reactive protein levels in patients with coronary artery ectasia versus patients with obstructive coronary artery disease. Am J Cardiol. 2004; 94:1303–1306.

15. Tokgozoglu L, Ergene O, Kinay O, Nazli C, Hascelik G, Hoscan Y. Plasma interleukin-6 levels are increased in coronary artery ectasia. Acta Cardiol. 2004; 59:515–519.

16. Turhan H, Erbay AR, Yasar AS, et al. Plasma soluble adhesion molecules; intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin levels in patients with isolated coronary artery ectasia. Coron Artery Dis. 2005; 16:45–50.

17. Japp AG, Cruden NL, Amer DA, et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008; 52:908–913.

18. Ellinor PT, Low AF, Macrae CA. Reduced apelin levels in lone atrial fibrillation. Eur Heart J. 2006; 27:222–226.

19. Li Z, Bai Y, Hu J. Reduced apelin levels in stable angina. Intern Med. 2008; 47:1951–1955.

20. Kadoglou NP, Lampropoulos S, Kapelouzou A, et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease--KOZANI STUDY. Transl Res. 2010; 155:238–246.

21. Ashley EA, Powers J, Chen M, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 2005; 65:73–82.

22. Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol. 2007; 102:518–528.

23. Li L, Li L, Xie F, et al. Jagged-1/Notch3 signaling transduction pathway is involved in apelin-13-induced vascular smooth muscle cells proliferation. Acta Biochim Biophys Sin (Shanghai). 2013; 45:875–881.

24. Daviaud D, Boucher J, Gesta S, et al. TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J. 2006; 20:1528–1530.

25. El-Shehaby AM, El-Khatib MM, Battah AA, Roshdy AR. Apelin: a potential link between inflammation and cardiovascular disease in end stage renal disease patients. Scand J Clin Lab Invest. 2010; 70:421–427.

26. Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. 2004; 25:401–408.

27. Ayhan SS, Oztürk S, Erdem A, et al. Relation of neutrophil/lymphocyte ratio with the presence and severity of coronary artery ectasia. Turk Kardiyol Dern Ars. 2013; 41:185–190.

28. Sincer I, Aktürk E, Açikgöz N, Ermiş N, Koşar MF. Evaluation of the relationship between serum high sensitive C-reactive protein and the elasticity properties of the aorta in patients with coronary artery ectasia. Anadolu Kardiyol Derg. 2011; 11:414–420.

29. Malyszko J, Malyszko JS, Pawlak K, Wolczynski S, Mysliwiec M. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc. 2008; 40:3466–3469.

30. Dagli N, Ozturk U, Karaca I, et al. Adiponectin levels in coronary artery ectasia. Heart Vessels. 2009; 24:84–89.